Pharm

Benralizumab

search

Benralizumab, Fasenra

  • Indications
  1. See Asthma Monoclonal Antibody
  2. Third-line agents for refractory, Type 2 Asthma (Allergic Asthma or Eosinophilic Asthma, represents 50% of Asthma)
    1. Despite long acting Bronchodilator and Inhaled Corticosteroids
  3. One of the following findings present
    1. Blood Eosinophils >150/uL
    2. Sputum Eosinophils >2%
    3. Ferrous Nitrous Oxide >20 parts per billion
    4. Maintenance oral Corticosteroids required
  • Precautions
  1. Treat Helminth infections prior to starting therapy
  • Dosing
  1. May be used in age >=12 years old U.S. (>=18 years old Canada)
  2. Dose 30 mg SQ every 4 weeks for 3 doses, then every 8 weeks
  3. Subcutaneous (SQ) injection sites include upper arm, Abdomen and thigh
  • Mechanism
  1. Interleukin-5 Antagonist (alpha-directed cytolytic Monoclonal Antibody, IgG1 Kappa)
    1. Similar to Mepolizumab
  2. Binds Interleukin 5 receptor on Eosinophils and Basophils (Asthma-related inflammatory cells)
    1. Marks these inflammatory cells for Natural Killer Cell mediated death
  • Safety
  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation
  • Adverse Effects
  • References
  1. (2022) Comparison of Asthma Medications, Presc Lett, #381217
  2. (2020) Drugs for Asthma, Med Lett Drug Ther 62: 193-200
  3. (2018) Biologics for Asthma, Presc Lett
  4. Narasimhan (2021) Am Fam Physician 103(5): 286-90 [PubMed]
  5. Raymond (2023) Am Fam Physician 107(4): 358-68 [PubMed]
    1. Ortega (2014) N Engl J Med 371(13): 1198-207 [PubMed]